MarketInOut Stock Screener Log In | Sign Up

Viridian Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Viridian Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,794.92 mln
Float106 mln
Earnings Date11/04/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

207
Highly suspicious

1-Year Forecast

36.20
Exceptional upside

Relative Strength

98 / 100
Top performer

Debt / Equity

0.37
Low leverage

Pre-Tax Margin

-544%
Severely loss-making

Business Description

Viridian Therapeutics is a biopharmaceutical company focused on developing medicines for rare and serious conditions, with a particular emphasis on thyroid eye disease and Graves' disease. The company is advancing several drug candidates that work by blocking specific proteins involved in these conditions, including treatments given by injection under the skin as well as through a vein. Founded in 2010 and based in Waltham, Massachusetts, the company rebranded from Miragen Therapeutics in 2021.

Key Fundamentals

EPS-3.39
ROE-63.68
RPS0.74
ROIC-1,147
ROA-49.04
Interest Cover-21.40
EBITDA, mln-370
EV / EBITDA-5.37
EV / EBIT-5.36
Revenue, mln71.13
EV / Revenue27.98

Quote Details

Last 24.67
Change -0.13 (-0.52%)
Open 24.77
Volume 1,709,583
Turnover 42,175,412
Average Volume 2,037,409

Financial Ratios

Pre-Tax Profit Margin-544
Leverage Ratio1.66
Current Ratio16.95
Price / Book4.84
Price / Tangible Book4.93
Debt / Equity0.37
Price / Sales27.75

Financial Strength

Altman Z-Score1.82
Piotroski F-Score 4 / 9
Beneish M-Score207
1-Year Target Price36.20
Short Ratio8.44
Short % of Float16.47

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 10.28% 94 / 100   
1 Month 29.91% 98 / 100   
2 Months 25.23% 94 / 100   
6 Months 83.83% 98 / 100   
1 Year 7.21% 63 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog